鼻内糖皮质激素喷雾与鼻出血风险:系统评价与Meta分析
该系统评价通过Medline、Embase、Web of Science、PubMed Central和Cochrane数据库检索截至2018年2月1日的英文随机对照试验,纳入72项报告鼻出血发生率的鼻内糖皮质激素治疗过敏性鼻炎研究。Meta分析显示所有鼻内糖皮质激素总体鼻出血相对风险为1.48(95%CI,1.32-1.67)。作者结论认为,虽然各药物间鼻出血差异效应未明确证实,但Meta分析确认与安慰剂相比鼻内糖皮质激素增加鼻出血风险。
要点
- 所有鼻内糖皮质激素总体鼻出血相对风险为1.48(95%CI,1.32-1.67)。
- 鼻出血风险最高的药物为倍氯米松氢氟烷烃、糠酸氟替卡松、糠酸莫米松和丙酸氟替卡松。
- 倍氯米松水性、环索奈德氢氟烷烃和环索奈德水性鼻出血风险最低。
核心结论
- 虽然各鼻内糖皮质激素药物间对鼻出血的差异效应未明确证实,但该Meta分析确认与安慰剂相比,使用鼻内糖皮质激素治疗过敏性鼻炎的患者鼻出血风险增加。
研究设计与样本
- 系统评价与Meta分析,按照PRISMA标准进行,检索Medline、Embase、Web of Science、PubMed Central和Cochrane数据库截至2018年2月1日的英文随机对照试验。
- 共识别949项研究,其中72项符合分析标准。
- 对每项纳入研究进行条目化偏倚风险评估,并对每种鼻内糖皮质激素的鼻出血相对风险进行Meta分析。
主要发现
- 所有鼻内糖皮质激素总体鼻出血相对风险为1.48(95%CI,1.32-1.67)。
- 鼻出血风险最高的鼻内糖皮质激素为倍氯米松氢氟烷烃、糠酸氟替卡松、糠酸莫米松和丙酸氟替卡松。
- 鼻出血风险最低的鼻内糖皮质激素为倍氯米松水性、环索奈德氢氟烷烃和环索奈德水性。
- 关于布地奈德、曲安奈德和氟尼缩松的鼻出血结论因研究数量少和异质性高而受限。
局限性
- 关于布地奈德、曲安奈德和氟尼缩松的鼻出血结论因研究数量少和异质性高而受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intranasal corticosteroids (INCSs) are widely utilized for the treatment of allergic rhinitis. Epistaxis is a known adverse effect of INCSs, but it is not known if the risk of epistaxis differs among INCSs. DATA SOURCES: Systematic review of primary studies identified through Medline, Embase, Web of Science, PubMed Central, and Cochrane databases. REVIEW METHODS: Systematic review was conducted according to the PRISMA standard. English-language studies were queried through February 1, 2018. The search identified randomized controlled trials of INCSs for treatment of allergic rhinitis that reported incidence of epistaxis. An itemized assessment of the risk of bias was conducted for each included study, and meta-analysis was performed of the relative risk of epistaxis for each INCS. RESULTS: Of 949 identified studies, 72 met the criteria for analysis. Meta-analysis demonstrated an overall relative risk of epistaxis of 1.48 (95% CI, 1.32-1.67) for all INCSs. The INCSs associated with the highest risk of epistaxis were beclomethasone hydrofluoroalkane, fluticasone furoate, mometasone furoate, and fluticasone propionate. Beclomethasone aqueous, ciclesonide hydrofluoroalkane, and ciclesonide aqueous were associated with the lowest risk of epistaxis. Conclusions about epistaxis with use of budesonide, triamcinolone, and flunisolide are limited due to the low number of studies and high heterogeneity. CONCLUSIONS: While a differential effect on epistaxis among INCS agents is not clearly demonstrated, this meta-analysis does confirm an increased risk of epistaxis for patients using INCSs as compared with placebo for treatment of allergic rhinitis.
引用
- Wu EL, Harris WC, Babcock CM, et al. Epistaxis Risk Associated with Intranasal Corticosteroid Sprays: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2019. PMID: 30779679. doi:10.1177/0194599819832277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。